14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
COCP vs ENTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Cocrystal Pharma, Inc. (COCP) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). COCP carries a Unified Composite Score of 38.7/100 (SELL) at $1.01 (N/M Forward P/E, -3063.6% operating margin), whereas ENTX carries 53.5/100 (HOLD) at $3.01 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (53.5/100 HOLD vs. COCP 38.7/100 SELL) and 1.07β · 45% Vol risk profile, whereas COCP leads top-line expansion (+26.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Competes within the Biotechnology value chain with $541.6M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ COCP vs ENTX Key Questions & Quantitative Answers
As of Nov 17, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Cocrystal Pharma, Inc. (COCP) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). COCP carries a Unified Composite Score of 38.7/100 (SELL) at $1.01 (N/M Forward P/E, -3063.6% operating margin), whereas ENTX carries 53.5/100 (HOLD) at $3.01 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (53.5/100 HOLD vs. COCP 38.7/100 SELL) and 1.07β · 45% Vol risk profile, whereas COCP leads top-line expansion (+26.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
COCP leads the Growth & Scale pillar: COCP posts +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin), compared with ENTX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2011 to FY2025), COCP cumulative revenue shifted +0.0% while ENTX shifted N/A. In operating R&D and SG&A reinvestment, COCP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTX.
COCP screens cheaper on headline valuation multiples. COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 47.3x EV/Revenue (unreported FCF margin), whereas ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against COCP (-311.7% ROE) versus ENTX (-20.3% ROE) capital efficiency.
In options market volatility and institutional positioning, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.97β · 55% Vol realized risk). By comparison, ENTX carries 113.8% implied volatility (32nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 45% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.